
---
nice.evidencecategory: 
---

### Evidence Statement CG66ES215
The analysis suggested that there was a risk associated with dual antiplatelet therapy in the
asymptomatic group since among the 3,284 asymptomatic patients there was a 6.6% relative
increase in the rate of primary events with clopidogrel plus aspirin, compared to 5.5% with
placebo (see table 15.3). Level 1++

[@Bhatt_2006]

